Piramal Builds GI Play With OTC Acquisitions
This article was originally published in Scrip
Piramal Enterprises' consumer products unit has acquired five brands from Organon India Pvt Ltd and MSD BV for INR920m ($13.8m), as it expands its offering in the fast growing gastrointestinals segment in India.
You may also be interested in...
India’s Piramal group continues its buying spree, snapping up Mallinckrodt’s intrathecal therapy business, as it seeks limited competition niches to plough deeper into the $20bn-plus global generic injectable hospital drugs market.
A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.
Glenmark hopes complex and respiratory products including a potential filing for generic Flovent pMDI can restore some lost sheen of its US business going forward, but a compliance comeback for its Monroe site may be pivotal to deliver material gains.